title: PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene study.
abstract: Phospholipid transferprotein (PLTP) mediates both net transfer and exchange of phospholipids between different lipoproteins. Although many studies have investigated the role of PLTP in atherogenesis, the role of PLTP in atherosclerotic diseases is unclear. We investigated the association of serum PLTP activity with the incidence of a combined endpoint (myocardial infarction and cardiovascular death) and its relation to other markers of atherosclerosis in 1,085 patients with angiographically documented coronary artery disease (CAD). In the median follow-up of 5.1 years, 156 patients had suffered from the combined endpoint of myocardial infarction or cardiovascular death including 47 of 395 patients who were on statins at baseline. In Kaplan-Meyer analyses serum PLTP activity was not associated with the combined endpoint in all patients. However, in the subgroup of patients receiving statins at baseline, PLTP was shown to be a significant predictor of cardiovascular outcome (P = 0.019), and this also remained stable in univariate (P = 0.027) and multivariate cox regression analyses (P = 0.041) including potential confounders (classical risk factors, HDL cholesterol (HDL-C), and others). We showed in our study that, under statin treatment, high plasma PLTP activity was related to fatal and nonfatal cardiovascular events in CAD patients.
authors.affiliation: Department of Medicine III, Martin Luther-University Halle-Wittenberg, Germany. axel.schlitt@medizin.uni-halle.de
authors.forename: Axel
authors.initials: A
authors.lastname: Schlitt
authors.forename: Stefan
authors.initials: S
authors.lastname: Blankenberg
authors.forename: Christoph
authors.initials: C
authors.lastname: Bickel
authors.forename: Karl J
authors.initials: KJ
authors.lastname: Lackner
authors.forename: Gunnar H
authors.initials: GH
authors.lastname: Heine
authors.forename: Michael
authors.initials: M
authors.lastname: Buerke
authors.forename: Karl
authors.initials: K
authors.lastname: Werdan
authors.forename: Lars
authors.initials: L
authors.lastname: Maegdefessel
authors.forename: Uwe
authors.initials: U
authors.lastname: Raaz
authors.forename: Hans J
authors.initials: HJ
authors.lastname: Rupprecht
authors.forename: Thomas
authors.initials: T
authors.lastname: Munzel
authors.forename: Xian-Cheng
authors.initials: XC
authors.lastname: Jiang
mesh_terms: D000368:Aged; D050197:Atherosclerosis / Q000097:blood / Q000209:etiology / Q000401:mortality; D016022:Case-Control Studies; D003324:Coronary Artery Disease / Q000097:blood* / Q000150:complications / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000209:etiology / Q000401:mortality; D049294:Phospholipid Transfer Proteins / Q000097:blood*; D011379:Prognosis; D012307:Risk Factors
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; C493430:PLTP protein, human; D049294:Phospholipid Transfer Proteins